Pelthos Therapeutics Inc. (PTHS) Stock Analysis & Investment Frameworks
Pelthos Therapeutics Inc. (PTHS) stock analysis on Invetso. Review Pelthos Therapeutics Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Pelthos Therapeutics Inc. Company Overview
- Exchange: New York Stock Exchange Arca
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
Pelthos Therapeutics Inc. Key Financial Metrics
- Market Cap: $77.14M
- Revenue: $16.80M
- ROE: -218.94%
- ROIC: -49.39%
- Dividend Yield: N/A
About Pelthos Therapeutics Inc.
Pelthos Therapeutics Inc. operates as a biopharmaceutical enterprise dedicated to developing and commercializing innovative medical treatments that address significant, unmet patient needs. Its primary offerings include ZELSUVMI, a medication specifically indicated for the treatment of molluscum contagiosum in individuals aged one year and older. Furthermore, the company leverages NITRICIL, an exclusive technological platform grounded in nitric oxide research. Established in 2002, this Durham, North Carolina-based firm was previously known as Channel Therapeutics Corporation, before rebranding to Pelthos Therapeutics Inc. in July 2025.
Pelthos Therapeutics Inc. Investment Frameworks
Invetso analyzes Pelthos Therapeutics Inc. (PTHS) across the following frameworks:
- Pelthos Therapeutics Inc. 10Y Growth Potential
- Pelthos Therapeutics Inc. Scenario Analysis
- Pelthos Therapeutics Inc. Risks & Opportunities
- Pelthos Therapeutics Inc. Economic Moat
- Pelthos Therapeutics Inc. Business Model
- Pelthos Therapeutics Inc. Management
- Pelthos Therapeutics Inc. SWOT Analysis
- Pelthos Therapeutics Inc. Porter's 5 Forces
- Pelthos Therapeutics Inc. PESTLE Analysis
- Pelthos Therapeutics Inc. ESG Analysis